Company Profile
Privately held, UK-based Ingenion Medical Limited is developing, manufacturing, and commercializing a family of products for chronic urinary retention and incontinence patients. cymactive™, its lead product, is a novel urinary catheter which can remain in-dwelling for up to 30 days, a dramatic quality of life improvement versus legacy solutions that often require multiple catheters in a single day, a common cause of infection and source of medical waste.
Approach to Healthcare
Dedicated to putting men back in control of their urinary retention. We have a CE Mark for our cymactive™ 2.0R, the company’s novel indwelling catheter designed to mimic natural urination. cymactive™ has been designed with the patient in mind to provide a better solution compared to both Foley-type catheters and intermittent catheters. The four primary benefits the company intends to demonstrate are:
1 – Improve patient’s quality of life, reduce anxiety and comfort after insertion,
2 – Minimise the causes of Catheter-Associated Urinary Tract Infections (CAUTIs),
3 – Promote natural bladder function and
4 – Reduce environmental waste
Impact of Products/Services on Healthcare:
A disruptive new device which could help reduce the billions spent by the NHS and the EU healthcare systems on treating Catheter-Associated Urinary Tract Infections (CAUTIs) has received European marketing authorization today. In all, 15%-25% of hospitalized patients and 5% of residents in elderly homes in Europe have a urinary catheter.
Innovation
cymactive™ uses a Malecot anchor, a four-winged flange, in the bladder with drainage at the base to allow patients to have a complete void while urinating. cymactive™ is approved to remain securely in-situ for up to 30 days. With cymactive™’s innovative UroValve™, a patient or patient’s carer uses an external magnet to activate a valve in the catheter within the urethra allowing the natural and complete emptying of the bladder at the patient’s convenience. Entirely internal, cymactive™ is discreet with only two slender removal threads extending from the penis. This design combines the stability of a Foley catheter with the autonomy and bladder function of an intermittent catheter.
Future Direction
A randomized controlled trial (RCT) called ACCTUATE will be running in the UK with NHS hospitals comparing cymactive™ versus Foley users over 90 days. UK Government grants have run and continue to run on expanding the core technology into female and male incontinence as well as female urinary retention. Working with hospitals and the community to demonstrate the Patient and Healthcare Professional benefits of the product versus traditional catheters.